Physician profile
Rylan Wells
NPI 1528788809
$3,273.63
in general payments reported to CMS, 2019-2025
26 companies · $916 in 2025
The $916 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $97.47 · 2023: $1,430 · 2024: $830 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,977 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,977.17 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $760.90 | 2023-2025 | Erleada, Akeega, Balversa |
| Sumitomo Pharma America, INC. | $368.95 | 2023-2025 | Gemtesa, Orgovyx |
| Myriad Genetic Laboratories, INC. | $266.39 | 2023-2025 | Prolaris |
| Merck Sharp & Dohme LLC | $261.07 | 2022-2025 | Lynparza, Welireg, Keytruda |
| Accord Healthcare, INC. | $222.81 | 2023-2025 | |
| Endo Pharmaceuticals INC. | $201.49 | 2022-2024 | Aveed, Xiaflex, Edex |
| Astellas Pharma US INC | $198.99 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $184.39 | 2023-2025 | |
| Endo USA, INC. | $127.28 | 2024-2025 | Xiaflex, Aveed |
| Teleflex LLC | $104.76 | 2022-2023 | Urolift |
| Procept Biorobotics Corporation | $88.42 | 2024 | Aquabeam System |
| Urogen Pharma, INC. | $84.17 | 2025 | |
| Dendreon Pharmaceuticals LLC | $76.89 | 2024-2025 | Provenge |
| Novartis Pharmaceuticals Corporation | $60.55 | 2025 | |
| Pfizer INC. | $49.58 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $31.24 | 2025 | Xyosted |
| Tempus Ai, INC | $24.96 | 2025 | Xt Cdx |
| 180 Medical, INC. | $24.07 | 2025 | Gentlecath Glide |
| Sun Pharmaceutical Industries INC. | $19.64 | 2022 | |
| Boston Scientific Corporation | $18.91 | 2024 | Lithoclast |
| Astrazeneca Pharmaceuticals LP | $18.46 | 2022 | |
| Verity Pharmaceuticals INC. | $17.66 | 2024 | Trelstar |
| Vertex Pharmaceuticals Incorporated | $17.42 | 2025 | |
| Mission Pharmacal Company | $16.32 | 2023 | Uribel |
| Tolmar, INC. | $15.83 | 2025 | Jatenzo, Eligard |
| Myovant Sciences INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rylan Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.